This inventor holds 6 USPTO granted patents and 13 published patent applications and 5 EPO patents. Top assignees: Csl Behring Gene Therapy, Inc., Csl Gene Therapy Pty Ltd., Calimmune, Inc.. Active years: 2018-2023.
Company Filing History:
4 out of 5 
3 out of 4 
2 out of 3 Years Active: 2018-2023
Title: The Innovations of Jeffrey S. Bartlett
Introduction
Jeffrey S. Bartlett is a prominent inventor based in Columbus, OH (US). He has made significant contributions to the field of gene therapy, holding a total of six patents. His work focuses on innovative methods for treating genetic disorders, particularly those related to hemoglobinopathies.
Latest Patents
Among his latest patents is a groundbreaking invention titled "Compositions and methods for treating beta-hemoglobinopathies." This patent describes expression vectors that include nucleic acid sequences for anti-HPRT RNAi and gamma globin genes. These vectors are designed to genetically correct conditions such as sickle cell disease and β-thalassemia. Another notable patent is for the "Bio-production of lentiviral vectors," which outlines a method for generating stable producer cell lines. This innovation enhances the reproducibility of high titer lentiviral stocks while addressing biosafety concerns.
Career Highlights
Throughout his career, Jeffrey has worked with notable companies in the field, including CSL Behring Gene Therapy, Inc. and CSL Gene Therapy Pty Ltd. His expertise in gene therapy has positioned him as a key figure in the development of advanced therapeutic techniques.
Collaborations
Jeffrey has collaborated with esteemed colleagues such as Chi-Lin Lee and Geoffrey Phillip Symonds. These partnerships have furthered his research and contributed to the advancement of gene therapy technologies.
Conclusion
Jeffrey S. Bartlett's innovative work in gene therapy has led to significant advancements in the treatment of genetic disorders. His contributions through patents and collaborations continue to impact the field positively.